[29P01-087S] Functional roles of the novel RING finger E3 ubiquitin ligase LINCR in fulminant inflammatory diseases

○Takumi Yokosawa¹, Yuki Nada¹, Yusuke Hirata¹, Takuya Noguchi¹, Atsushi Matsuzawa¹ (1. Lab. of Health Chem., Grad. Sch. of Pharmaceut. Sci., Tohoku Univ.)

[29P01-088S] The roles of secretary protein neudesin in inflammatory macrophages

○Yushi Nishiyama¹, kouki inaoka¹, yuki uemura¹, yoneda makiko¹, nakayama yoshiaki¹, masuda yuki¹, itou nobuyuki², konishi moritika¹ (1. Kobe Pharm. Univ., 2. kyoto univ.)

[29P01-089S] Secretory factor Neudesin promotes tumor growth by inhibiting the activity of dendritic cells

○Takumi Tanigaki¹, Tetsuya Takama¹, Aduki Murata¹, Noriyuki Matsumae¹, Yusuke Abe¹, Yuki Masuda¹, Yoshiaki Nakayama¹, Nobuyuki Itoh², Morichika Konishi¹ (1. Kobe Pharm. Univ., 2. Grad. Sch. Pharm. Sci., Kyoto Univ.)

[29P01-090S] Analysis of therapeutic effect by BAMP developed for BNCT

○Haruna Uto¹, Haruka Arita¹, Nobuyuki Kamegawa², Ryota Takeuchi², Hitoshi Hori^2,3, Machiko Honda¹, Shigeyuki Kon¹, Yuhki Sato¹, Makoto Shirakawa^1,4 (1. Fukuyama Univ., 2. Morita Pharmaceutical Ind.,Ltd., 3. Niigata Univ., 4. Tsukuba Univ.)

Withdrawn

[29P01-091S] [Withdrawn]

[29P01-092S] Nanaomycin A inhibits activation of the NLRP3-inflammasome

○Yudai Matsui¹, Naoki Takemura², Manabu Taura², Tatsuya Saitoh² (1. Sch. Pharm. Sci., Osaka Univ., 2. Grad. Sch. Pharm. Sci., Osaka Univ.)

[29P01-093S] Celastrol promotes apoptotic cell death in LPS-treated macrophages

○Miyuu Tanaka¹, Atsushi Koike¹, Makio Shibano¹, Ko Fujimori¹ (1. Osaka Univ. Pharm Sci.)

[29P01-094] Statins attenuate antiviral IFN-β and ISG expression via inhibiting IRF3 and JAK/STAT signaling in poly(I:C)-treated hyperlipidemic mice and macrophages

○Atsushi Koike¹, Ko Fujimori¹ (1. Osaka Univ. Pharm Sci.)

[29P01-095S] Roles of the switch in antiviral responses in regulating inflammatory diseases in the central nervous system

○Keiji Nozaki¹, Tomohiko Okazaki¹, Yukiko Gotoh^1,2 (1. Grad. Sch. Pharmaceutical Sci., the Univ. of Tokyo, 2. International Research Center for Neurointelligence)

[29P01-096S] Anti-inflammatory effect of TNFR1-selective antagonisticTNF mutant protein and its derivative in murine hepatitismodel.

○Nao NISHIOKU¹, Masaki INOUE^1,2, Haruhiko KAMADA^2,3, Shin-ichi TSUNODA^1,2,3 (1. Fac. Pharm. Sci., Kobe Gakuin Univ., 2. NIBIOHN, 3. MEIC, Osaka Univ.)

[29P01-097S] A TNFR2-selective agonistic TNF mutein suppressed inflammation in contact hypersensitivity model mice.

○Koki Kuge¹, Masaki Inoue^1,2, Taichi Okumura¹, Takao Tone¹, Shin-ichi Tsunoda^1,2,3 (1. Fac.Pharm. Sci., Kobe Gakuin Univ., 2. NIBIOHN, 3. MEIC, Osaka Univ.)

[29P01-098S] Generation and characterization of TNFR1-selective antagonistic TNF mutant Fc-fusion protein for the treatment of rheumatoid arthritis in mice.

○Risako Sekiya¹, Masaki Inoue^1,2, Haruhiko Kamada^2,3, Shin-ichi Tsunoda^1,2,3 (1. Fac. Pharm. Sci., Kobe Gakuin Univ., 2. NIBIOHN,, 3. MEIC, Osaka Univ.)

[29P01-099S] A TNFR2-selective and agonistic TNF mutein derivative enhances the proliferation of murine regulatory T cells.

○Taichi Okumura¹ (1. 1Fac. Pharm. Sci., Kobe Gakuin Univ.)

[29P01-100S] Behavior of tumor-infiltrating Tregs and MDSCs in B16 melanoma-transplanted TNFR2-deficient mice.

○Takao Tone¹, Masaki Inoue^1,2, Taichi Okumura¹, Kouki Kuge¹, Kanako Yamashita¹, Shin-ichi Tunoda^1,2,3 (1. Fac. Pharm. Sci., Kobe Gakuin Univ., 2. NIBIOHN, , 3. MEIC, Osaka Univ.)

[29P01-101S] Anti-inflammatory effect of Mallotus philippinensis bark extracts

○Ayaka Iwasaki^1,2, Sae Asayama^1,2, Syunya Sahara^3,4, Tadashi Okamoto², Kazuhiko Hamada³, Koichi Nakaoji^3,4, Masamitsu Ichihashi², Ken-ichi Mizutani¹ (1. Grad. Sch. Pharm. Sci., Kobe Gakuin Univ., 2. Fac. Pharm., Kobe Gakuin Univ., 3. PIAS Co., Ltd., 4. PIAS Collaborative Research., Osaka Univ.)

[29P01-102S] Age-related exacerbation of allergic responses in vivo.

○Shunsuke Okada¹, Yusho Hashimoto², Kousei Kawai², Naohide Hirashima², Ryo Suzuki¹ (1. Fac. Pharm. Sci., Inst. Med. Pharm. and Health Sci., Kanazawa Univ., 2. Graduate School of Pharmaceutical Sciences, Nagoya City University)

[29P01-103S] Study for molecular mechanisms of mast cell-neutrophil communication.

○Nanako Yokoji¹, Komomo Ito¹, Ryo Suzuki¹ (1. Fac. Pharm. Sci., Inst. Med. Pharm. and Health Sci., Kanazawa Univ.)

[29P01-104] Analysis of the mechanism of attenuation of allergic responses by infection-like stimulation: Age-related differences in LPS reactivity of macrophages

○Michihiko Abe¹, Ryosuke Segawa¹, Kodai Abe¹, Natsumi Mizuno², Noriyasu Hirasawa¹ (1. Grd. Sch. Pharmaceutical Sci., Tohoku Univ., 2. Health Sciences University of Hokkaido)

[29P01-105S] Development of novel monoclonal antibodies against immunosuppressive HLA-G2 protein

○Naruki Akaiwa¹, Kimiko Kuroki¹, Kazuma Hikichi¹, Atsushi Furukawa¹, Naoyoshi Maeda¹, Katsumi Maenaka¹ (1. Grad. Sch. Pharm. Sci., Hokkaido Univ.)

[29P01-106S] Development of methimazole derivatives with reduced side effect for the treatment of autoimmune diseases

○Mami Fukunaga¹, Takashi Nishiyama¹, Machiko Honda¹, Tominari Choshi¹, Shigeyuki Kon¹ (1. Pharm., Fukuyama Univ.)

[29P01-107S] Production and characterization of an anti-human BAFF receptor monoclonal antibody for therapeutic application.

○Sakura Murase¹, Masaki Inoue^1,2, Yasuhiro Abe³, Tomoko Ise², Satoshi Nagata², Shin-ichi Tsunoda^1,2,4 (1. Fac. Pharm. Sci., Kobe Gakuin Univ, 2. NIBIOHN, 3. NIHS, 4. MEIC, Osaka Univ.)

[29P01-108S] Regulation of mutated Cytokine receptor like factor 2 expression by glycosylation

○Rio Yamamoto¹, Ryosuke Segawa¹, Hiyori Kato¹, Noriyasu Hirasawa¹ (1. Grad. Sch. Pharm Sci., Tohoku Univ.)

[29P01-109S] Molecular mechanisms underlying expression of sialyl Lewis X glycan antigen on mouse B cells

○Daichi Komiyama¹, Tomohiro Takezoe¹, Ryuji Matsumura², Shigetaka Sekine¹, Shogo Nishida¹, Jotaro Hirakawa¹, Hiroto Kawashima^1,2 (1. Grad. Sch. Pharm., Chiba Univ., 2. Sch. Pharm. Sci., Univ. Shizuoka)

[29P01-110] Studies on optimization of immune tolerance therapy utilizing naturally occurring regulatory T cell

○Yuya Yoshida¹, Kazushi Hirata¹, Ryota Mamiya¹, Aimi Ueji¹, Chihiro Tominaga¹, Shohei Nakano^1,2, Norihisa Mikami³, Takumi Tsuji¹, Takeyuki Kohno¹ (1. Fac. Pharm. Sci., Setsunan Univ., 2. Dept. Pharm., Kansai Med. Univ. Kori Hosp., 3. IFReC, Osaka Univ.)

[29P01-111S] Butyrophilin3A1 expression is a biomarker for ex-vivo expansion of γδT cells

○Maho Omura¹, Mako Tomogane¹, Yuki Toda¹, Shigekuni Hosogi¹, Eishi Ashihara¹ (1. Kyoto Pharmaceutical Univ.)

[29P01-112] Role of Abcd1-deficient CD4-positive T cells in adrenoleukodystrophy

○Masashi Morita¹, Mayu Oishi¹, Reina Maeda¹, Eigo Kawahara¹, Takanori So¹ (1. Grad. Sch. Med. Pharm., Univ. Toyama)

[29P01-113S] Application of the highly active form of chemokine XCL1 to transcutaneous vaccine system for efficient induction of memory CTL

○Mayuko Otsuki¹, Momo Kamei¹, Kazuhiko Matsuo¹, Haruka Imanishi¹, Yuta Hara¹, Ying-Shu Quen², Fumio Kamiyama², Naoki Okada³, Takashi Nakayama¹ (1. Kindai Univ. Faculty of Pharmacy, 2. CosMED Pharmaceutical. Co. Ltd., 3. Graduate School of Pharmaceutical Sciences, Osaka Univ.)

[29P01-114] Identify the cytotoxic factor included in supernatant of tumor cell line

○Takuya Nishinakagawa¹, Mai Hazekawa¹, Daisuke Ishibashi¹ (1. Dept. Immuno. Mol. Pharm., Pharm Sci., Fukuoka Univ.)

[29P01-115] Organogermanium compound THGP suppresses inflammasome activitation by LPS / ATP or SARS-CoV-2 derived protein ORF3a

○Junya Azumi¹, Tomoya Takeda¹, Yasuhiro Shimada¹, Hisashi Aso², Takashi Nakamura¹ (1. Asai Germanium Research Institute Co.,Ltd., 2. Grad. Sch. Agricultural Sci., Tohoku Univ.)

[29P01-L002] Analysis of prostate cancer stem-like cell targeting mechanism in NK cells.

○Taiga Seki¹, Tomohiro Yano² (1. Grad. Sch. food and Nutritional Sci., Toyo Univ., 2. Res. Inst. Life Innovation, Toyo Univ.)

[29P01-L003] Modeling pulmonary fibrosis using alveolar organoid

○Rina Matsukiyo¹, Tatsuro Ogawa¹, Shigeyuki Shichino¹, Kazushige Shiraishi², Satoshi Ueha¹, Gaku Ichihara¹, Kouji Matsushima¹ (1. TUS, 2. The University of Pennsylvania)

Session information

[29P01] 生体の高次構造①